Xiamen Amoytop Biotech Co., Ltd. (SHA:688278)

Market Cap	31.67B
Revenue (ttm)	3.34B
Net Income (ttm)	939.58M
Shares Out	406.80M
EPS (ttm)	2.31
PE Ratio	33.70
Forward PE	23.01
Dividend	0.62 (0.80%)
Ex-Dividend Date	May 9, 2025

Volume	1,357,869
Average Volume	2,230,044
Open	77.58
Previous Close	77.87
Day's Range	77.30 - 79.05
52-Week Range	66.00 - 93.52
Beta	-0.22
RSI	54.42
Earnings Date	Oct 30, 2025

About Xiamen Amoytop Biotech

Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China and internationally. It offers various drug products, such as pegsomatropin injection, pegfilgrastim injection, molgramostim, filgrastim, and oprelvekin; active pharmaceutical ingredients (APIs); and reagents to treat viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd. was founded in 1996 and is headquartered in Xiamen, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 2,423
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688278

Financial Performance

In 2024, Xiamen Amoytop Biotech's revenue was 2.82 billion, an increase of 34.13% compared to the previous year's 2.10 billion. Earnings were 827.60 million, an increase of 49.00%.